Ulrich Martin

Ulrich Martin

STUTTGART, Germany I June 23, 2017 I Overlooked for many years, RNA languished as the ugly stepchild of nucleic acid vaccine development and was thought to be a poor choice for a therapeutic agent given its short half-life in vivo and its immunogenicity. But two of the main problems of messenger RNA (mRNA) technologies, i.e. stability and manufacturing, sufficiently have been solved and optimized nanoparticle carrer technologies enable targeted mRNA delivery in vivo.

The technological progress has made pilot projects feasible for biopharmaceutical and major pharma companies. Upfront payments of some of the collaboration agreements between key mRNA players and Big Pharma reached US$ 240 mln and US$ 310 mln, respectively. Some of the deals between mRNA companies and rare disease specialist biopharmaceutical companies have a potential value of up to US$ 2.4 bln and US$ 3.2 bln, respectively, if all milestones will be met. Over the last years, companies with mRNA technologies have attracted mroe than US$ 3.4 bln from equity investments and partnership payments. In addition, funding from governmental institutions and philanthropic organizations has been been crucial for development of mRNA technologies (vaccines and antibodies) for infectious diseases.

mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.

Scope of clinical mRNA applications



Cancer Vaccines

Infectious Disease Vaccines

In vivo Therapeutics

Gene Editing

- Standardized preselected

- Individualized
shared antigens

- Individualized neoantigens

- Prophylactic vaccines

- Therapeutic vaccines

- Synthetic self-amplifying mRNA vaccines for pandemic outbreaks

- Therapeutic proteins

- Therapeutic antibodies

- Ex vivo gene editing of gene defects

- In vivo gene editing of gene defects

- Ex vivo gene editing of autologous and allogeneic T-cells

In a new report released by La Merie Publishing, the competitive landscape of mRNA Vaccines & Therapeutics is described and analyzed for pipelines, technologies, stakeholders, financing and deals.

This report „mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals“ as of June 2017 brings you up-to-date regarding key players, key technologies, profiles of key mRNA vaccines and therapeutics in development, business deals and private and public financing rounds. The report analyzes the mRNA pipeline and stakeholders in the field. The report highlights the value of mRNA product candidates in terms of partnering terms and conditions, venture and private financing and non-dilutive funding.

About La Merie

La Merie Publishing is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com and www.PipelineReview.com, the Biologics News Center and Online Store of La Merie Publishing.

SOURCE: La Merie Publishing

STUTTGART, Germany I June 23, 2017 I Overlooked for many years, RNA languished as the ugly stepchild of nucleic acid vaccine development and was thought to be a poor choice for a therapeutic agent given its short half-life in vivo and its immunogenicity. But two of the main problems of messenger RNA (mRNA) technologies, i.e. stability and manufacturing, sufficiently have been solved and optimized nanoparticle carrer technologies enable targeted mRNA delivery in vivo.

The technological progress has made pilot projects feasible for biopharmaceutical and major pharma companies. Upfront payments of some of the collaboration agreements between key mRNA players and Big Pharma reached US$ 240 mln and US$ 310 mln, respectively. Some of the deals between mRNA companies and rare disease specialist biopharmaceutical companies have a potential value of up to US$ 2.4 bln and US$ 3.2 bln, respectively, if all milestones will be met. Over the last years, companies with mRNA technologies have attracted mroe than US$ 3.4 bln from equity investments and partnership payments. In addition, funding from governmental institutions and philanthropic organizations has been been crucial for development of mRNA technologies (vaccines and antibodies) for infectious diseases.

mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.

Scope of clinical mRNA applications



Cancer Vaccines

Infectious Disease Vaccines

In vivo Therapeutics

Gene Editing

- Standardized preselected

- Individualized
shared antigens

- Individualized neoantigens

- Prophylactic vaccines

- Therapeutic vaccines

- Synthetic self-amplifying mRNA vaccines for pandemic outbreaks

- Therapeutic proteins

- Therapeutic antibodies

- Ex vivo gene editing of gene defects

- In vivo gene editing of gene defects

- Ex vivo gene editing of autologous and allogeneic T-cells

In a new report released by La Merie Publishing, the competitive landscape of mRNA Vaccines & Therapeutics is described and analyzed for pipelines, technologies, stakeholders, financing and deals.

This report „mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals“ as of June 2017 brings you up-to-date regarding key players, key technologies, profiles of key mRNA vaccines and therapeutics in development, business deals and private and public financing rounds. The report analyzes the mRNA pipeline and stakeholders in the field. The report highlights the value of mRNA product candidates in terms of partnering terms and conditions, venture and private financing and non-dilutive funding.

About La Merie

La Merie Publishing is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com and www.PipelineReview.com, the Biologics News Center and Online Store of La Merie Publishing.

SOURCE: La Merie Publishing

STUTTGART, Germany I March 17, 2017 I Sales of branded originator biologics in 2016 continued to reach a record high of US$ 163 bln, a plus of 5.8% compared with the previous year. Growth drivers were therapeutic antibodies for treatment of cancer and inflammatory diseases, especially the emerging immuno-oncology antibodies and novel anti-inflammatory antibodies different from anti-TNF. Interestingly, sales of all anti-inflammatory antibodies including the anti-TNF family were 63% higher than those of the cancer antibodies. Nearly two-thirds of all biologics sales are attributable to antibodies, while 2016 sales of therapeutic proteins were 10% lower than those in 2015. Nearly all classes of therapeutic proteins except enzyme replacement therapies have seen a decline of sales in 2016.

A total of 42 biologic therapeutics reached blockbuster status with 2016 sales exceeding US$ 1 bln: 25 antibodies and 17 proteins. Eight biologics reached global sales in 2015 of more than US$ 5 bln. Four biologics were new in the blockbuster biologics list, among them the immune checkpoint modulator nivolumab which made it among the TOP 10 blockbuster biologics. Six biopharmaceutical companies posted biologics sales of more than US$ 10 bln in the year 2016.

The report „Blockbuster Biologics 2016: Sales of Recombinant Therapeutic Antibodies & Proteins“ can be acquired at La Merie Publishing’s News Center and Online Store www.PipelineReview.com: https://www.pipelinereview.com/index.php/store-online/blockbuster-biologics-2016-sales-of-recombinant-therapeutic-antibodies-proteins-detail

The report provides a compilation of the sales data of recombinant therapeutic proteins and antibodies in the calendar year 2016. Sales data were obtained from company publications and refer to branded products originating from companies based in regulated markets. All sales data were converted from their original, published currency into US$. Sales figures represent the sum of revenues in all territories where the products were marketed. Growth rates usually are listed as reported (in some cases on constant exchange rates).

Sales data are presented for each product within the respective class of biologics. The data were analyzed to establish a ranking list of blockbuster biologics with 2016 sales higher than US$ 1 bln. Another ranking list was prepared for companies according to biologics sales in 2016 and the percentage of antibody sales vs protein sales.

About La Merie

La Merie Publishing is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com and www.PipelineReview.com, the Biologics News Center and Online Store of La Merie Publishing.

SOURCE: La Merie Publishing

STUTTGART, Germany I March 17, 2017 I Sales of branded originator biologics in 2016 continued to reach a record high of US$ 163 bln, a plus of 5.8% compared with the previous year. Growth drivers were therapeutic antibodies for treatment of cancer and inflammatory diseases, especially the emerging immuno-oncology antibodies and novel anti-inflammatory antibodies different from anti-TNF. Interestingly, sales of all anti-inflammatory antibodies including the anti-TNF family were 63% higher than those of the cancer antibodies. Nearly two-thirds of all biologics sales are attributable to antibodies, while 2016 sales of therapeutic proteins were 10% lower than those in 2015. Nearly all classes of therapeutic proteins except enzyme replacement therapies have seen a decline of sales in 2016.

A total of 42 biologic therapeutics reached blockbuster status with 2016 sales exceeding US$ 1 bln: 25 antibodies and 17 proteins. Eight biologics reached global sales in 2015 of more than US$ 5 bln. Four biologics were new in the blockbuster biologics list, among them the immune checkpoint modulator nivolumab which made it among the TOP 10 blockbuster biologics. Six biopharmaceutical companies posted biologics sales of more than US$ 10 bln in the year 2016.

The report „Blockbuster Biologics 2016: Sales of Recombinant Therapeutic Antibodies & Proteins“ can be acquired at La Merie Publishing’s News Center and Online Store www.PipelineReview.com: https://www.pipelinereview.com/index.php/store-online/blockbuster-biologics-2016-sales-of-recombinant-therapeutic-antibodies-proteins-detail

The report provides a compilation of the sales data of recombinant therapeutic proteins and antibodies in the calendar year 2016. Sales data were obtained from company publications and refer to branded products originating from companies based in regulated markets. All sales data were converted from their original, published currency into US$. Sales figures represent the sum of revenues in all territories where the products were marketed. Growth rates usually are listed as reported (in some cases on constant exchange rates).

Sales data are presented for each product within the respective class of biologics. The data were analyzed to establish a ranking list of blockbuster biologics with 2016 sales higher than US$ 1 bln. Another ranking list was prepared for companies according to biologics sales in 2016 and the percentage of antibody sales vs protein sales.

About La Merie

La Merie Publishing is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com and www.PipelineReview.com, the Biologics News Center and Online Store of La Merie Publishing.

SOURCE: La Merie Publishing

STUTTGART, Germany I January 25, 2017 I The acquisition of oncolytic virus company BioVex by Amgen in late 2011 for up to US$ 1 bln has been a game changer for the field of oncolytic viruses, now recognized as a promising new therapeutic approach for cancer treatment. The approval of Amgen‘s herpes simplex oncolytic virus Imlygic in late 2015 further strengthened this trend as evidenced by the fact that total venture equity investment into oncolytic companies in the year 2016 was nearly 17-fold higher than that in 2010. Although the total economic value of all transactions with oncolytic viruses in the year 2016 was in excess of US$ 370 mln, it is only a marginal amount compared with the US$ 3.5 bln moved in transactions related to TCR and CAR T-cell therapies in the year 2015.

Big Pharma companies active in the immuno-oncology field and a few selected investors were among the first to realize the potential clinical and commercial value of oncolytic viruses. In the short term, combination of an oncolytic virus with an immune checkpoint inhibitor represents a quick path towards approval. Amgen and Merck are in the lead with a pivotal phase III combination trial. Early clinical data indiate synergistic efficacy without increased toxicity. Apart from direct cancer cell lysis, oncolytic viruses induce a tumor-specific systemic immunity which can be enhanced by combination with immune checkpoint inhibitors.

The next generation constructs of oncolytic viruses in development incorporate transgenes to locally express immune system co-stimulatory molecules, such as 4-1BB, CD40L, OX40 or CD80, but also the CD3 receptor to recruit T-cells, or even single chain antibodies for local anti-PD-1 action. If proven effective in clinical studies, this profile of oncolytic viruses could convert them again to stand-alone therapeutics independent from the combination with other immune checkpoint inhibitors (or stimulators).

In a new report released by La Merie Publishing, the competitive landscape of oncolytic virus stakeholders, technologies, pipelines, financing and deals is described and analyzed.

This report „The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities“ as of January 2017 brings you up-to-date regarding key players, key technologies, oncolytic virus products and projects, business deals and private and public financing rounds. The report analyzes the oncolytic virus pipeline and stakeholders in the field, especially among Big Pharma/Biotech and technology companies. The report highlights the value of oncolytic viruses in terms of partnering terms and conditions, venture and private financing, (initial) public offerings and mergers & acquisitions.

About La Merie

La Merie Publishing is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com and www.PipelineReview.com, the Biologics News Center and Online Store of La Merie Publishing.

SOURCE: La Merie Publishing

STUTTGART, Germany I January 25, 2017 I The acquisition of oncolytic virus company BioVex by Amgen in late 2011 for up to US$ 1 bln has been a game changer for the field of oncolytic viruses, now recognized as a promising new therapeutic approach for cancer treatment. The approval of Amgen‘s herpes simplex oncolytic virus Imlygic in late 2015 further strengthened this trend as evidenced by the fact that total venture equity investment into oncolytic companies in the year 2016 was nearly 17-fold higher than that in 2010. Although the total economic value of all transactions with oncolytic viruses in the year 2016 was in excess of US$ 370 mln, it is only a marginal amount compared with the US$ 3.5 bln moved in transactions related to TCR and CAR T-cell therapies in the year 2015.

Big Pharma companies active in the immuno-oncology field and a few selected investors were among the first to realize the potential clinical and commercial value of oncolytic viruses. In the short term, combination of an oncolytic virus with an immune checkpoint inhibitor represents a quick path towards approval. Amgen and Merck are in the lead with a pivotal phase III combination trial. Early clinical data indiate synergistic efficacy without increased toxicity. Apart from direct cancer cell lysis, oncolytic viruses induce a tumor-specific systemic immunity which can be enhanced by combination with immune checkpoint inhibitors.

The next generation constructs of oncolytic viruses in development incorporate transgenes to locally express immune system co-stimulatory molecules, such as 4-1BB, CD40L, OX40 or CD80, but also the CD3 receptor to recruit T-cells, or even single chain antibodies for local anti-PD-1 action. If proven effective in clinical studies, this profile of oncolytic viruses could convert them again to stand-alone therapeutics independent from the combination with other immune checkpoint inhibitors (or stimulators).

In a new report released by La Merie Publishing, the competitive landscape of oncolytic virus stakeholders, technologies, pipelines, financing and deals is described and analyzed.

This report „The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities“ as of January 2017 brings you up-to-date regarding key players, key technologies, oncolytic virus products and projects, business deals and private and public financing rounds. The report analyzes the oncolytic virus pipeline and stakeholders in the field, especially among Big Pharma/Biotech and technology companies. The report highlights the value of oncolytic viruses in terms of partnering terms and conditions, venture and private financing, (initial) public offerings and mergers & acquisitions.

About La Merie

La Merie Publishing is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com and www.PipelineReview.com, the Biologics News Center and Online Store of La Merie Publishing.

SOURCE: La Merie Publishing

STUTTGART, Germany I August 10, 2016 I Immunotherapy of B-cell malignancies with specifically targeted autologous T-cells most probably will see the first adoptive cell therapy products approved in the year 2017. Novartis, Kite Pharma and Juno Therapeutics are in a head-to-head race to be first on the market with anti-CD19 chimeric antigen receptor (CAR) T-cells. However, the success story with CD19 CAR T-cells is not as easily repeated with CAR T-cells directed against other targets in hematologic malignancies and - even more - in solid tumors. Limitations by lack of target specificity resulting in on-target, off-tumor toxicity, is one of the major hurdles associated with insufficient activity of current CAR constructs.

As a consequence, the limitations are adressed by a multitude of measures. Gene editing capabilities appears as a key technology not only to generate allogeneic CAR T-cells from donor cells or renewable, pluripotent stem cells, but also to bring CAR design and engineering to a new level of multiplex editing. Knock-out of auto-antigens or immune checkpoints, but also incorporation of on- and off switches for controlling of T-cell activity and enhance potency are some of the features enableb by genome editing of T-cells.

In a new report released by La Merie Publishing, the competitive landscape of CAR T-Cell stakeholders, technologies, pipelines, financing and deals is described and analyzed.

This report „TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs“ describes and analyzes the status of the adoptive cell therapy industry as of August 2016. The report covers autologous and allogeneic engineered chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapy candidates as well as natural killer (NK) cell and CAR engineered NK cells in research and development by biopharmaceutical companies. Cytotoxic lymphocytes (CTLs), donor lymphocyte infusions (TILs) and tumor infiltrating lymphocytes (TILs) complement the spectrum of the report.

About La Merie

La Merie Publishing is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com and www.PipelineReview.com, the Biologics News Center and Online Store of La Merie Publishing.

SOURCE: La Merie Publishing

STUTTGART, Germany I August 10, 2016 I Immunotherapy of B-cell malignancies with specifically targeted autologous T-cells most probably will see the first adoptive cell therapy products approved in the year 2017. Novartis, Kite Pharma and Juno Therapeutics are in a head-to-head race to be first on the market with anti-CD19 chimeric antigen receptor (CAR) T-cells. However, the success story with CD19 CAR T-cells is not as easily repeated with CAR T-cells directed against other targets in hematologic malignancies and - even more - in solid tumors. Limitations by lack of target specificity resulting in on-target, off-tumor toxicity, is one of the major hurdles associated with insufficient activity of current CAR constructs.

As a consequence, the limitations are adressed by a multitude of measures. Gene editing capabilities appears as a key technology not only to generate allogeneic CAR T-cells from donor cells or renewable, pluripotent stem cells, but also to bring CAR design and engineering to a new level of multiplex editing. Knock-out of auto-antigens or immune checkpoints, but also incorporation of on- and off switches for controlling of T-cell activity and enhance potency are some of the features enableb by genome editing of T-cells.

In a new report released by La Merie Publishing, the competitive landscape of CAR T-Cell stakeholders, technologies, pipelines, financing and deals is described and analyzed.

This report „TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs“ describes and analyzes the status of the adoptive cell therapy industry as of August 2016. The report covers autologous and allogeneic engineered chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapy candidates as well as natural killer (NK) cell and CAR engineered NK cells in research and development by biopharmaceutical companies. Cytotoxic lymphocytes (CTLs), donor lymphocyte infusions (TILs) and tumor infiltrating lymphocytes (TILs) complement the spectrum of the report.

About La Merie

La Merie Publishing is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com and www.PipelineReview.com, the Biologics News Center and Online Store of La Merie Publishing.

SOURCE: La Merie Publishing

STUTTGART, Germany I May 13, 2016 I Immunotherapy of cancer with direct or indirect use of T-cells is one of the most exciting fields in cancer research. Direct T-cell therapy implies the ex vivo engineering of autologous or allogeneic T-cells for tumor targeting by chimeric antigen receptors (CAR) or T-cell receptors (TCR). Despite stunning clinical results with CD19-targeted CAR T-cells, many major pharmaceutical companies have not embarked on adoptive cell therapy, probably because cell products are a world completely different from that of small molecules or recombinant proteins and antibodies.

Tremendous progress in bispecific antibody technologies during the last decade and the clinical success of a first generation bispecific T-cell engager (BiTE) antibody molecule directed against CD19 lead to an explosion of T-cell redirecting bispecific antibodies in clinical development. Within 18 months, the number of clinical stage T-cell or natural killer (NK) cells redirecting bispecific antibodies has increased from 4 to 21 and further 16 molecules could enter clinical development within the next 12 months. Data from these clinical studies in the next years will give valuable feedback for the further design of T-cell redirecting bispecific constructs.

In a new report released by La Merie Publishing, the competitive T-cell redirecting bispecific antibody stakeholders, technologies, pipelines and deals is described and analyzed.

This report „T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals“ provides up-to-date information about and analysis of 34 corporate players, 22 key technologies, 47 T-cell and NK-cell redirecting bispecific antibody profiles, business deals and private and public financing rounds.

The report analyzes the pipeline of T-cell and NK-cell redirecting bispecific antibody molecules regarding preferred targets, molecular constructs, dosing schedules, clinical experience, combination study plans, competition with other treatment modalities and the next wave of T-cell and NK-cell redirecting antibodies.

Preferences in bispecific antibody technologies are evaluated regarding drug candidate output, partnering, technological features and impact on clinical administration regimens.

The report highlights the commercial value of T-cell redirecting bispecific antibody immunotherautics in terms of drug prices, sales, company acquisition prices, economic terms of partnering deals, and private or public financing rounds.

About La Merie

La Merie Publishing is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com and www.PipelineReview.com, the Biologics News Center and Online Store of La Merie Publishing.

SOURCE: La Merie Publishing

STUTTGART, Germany I May 13, 2016 I Immunotherapy of cancer with direct or indirect use of T-cells is one of the most exciting fields in cancer research. Direct T-cell therapy implies the ex vivo engineering of autologous or allogeneic T-cells for tumor targeting by chimeric antigen receptors (CAR) or T-cell receptors (TCR). Despite stunning clinical results with CD19-targeted CAR T-cells, many major pharmaceutical companies have not embarked on adoptive cell therapy, probably because cell products are a world completely different from that of small molecules or recombinant proteins and antibodies.

Tremendous progress in bispecific antibody technologies during the last decade and the clinical success of a first generation bispecific T-cell engager (BiTE) antibody molecule directed against CD19 lead to an explosion of T-cell redirecting bispecific antibodies in clinical development. Within 18 months, the number of clinical stage T-cell or natural killer (NK) cells redirecting bispecific antibodies has increased from 4 to 21 and further 16 molecules could enter clinical development within the next 12 months. Data from these clinical studies in the next years will give valuable feedback for the further design of T-cell redirecting bispecific constructs.

In a new report released by La Merie Publishing, the competitive T-cell redirecting bispecific antibody stakeholders, technologies, pipelines and deals is described and analyzed.

This report „T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals“ provides up-to-date information about and analysis of 34 corporate players, 22 key technologies, 47 T-cell and NK-cell redirecting bispecific antibody profiles, business deals and private and public financing rounds.

The report analyzes the pipeline of T-cell and NK-cell redirecting bispecific antibody molecules regarding preferred targets, molecular constructs, dosing schedules, clinical experience, combination study plans, competition with other treatment modalities and the next wave of T-cell and NK-cell redirecting antibodies.

Preferences in bispecific antibody technologies are evaluated regarding drug candidate output, partnering, technological features and impact on clinical administration regimens.

The report highlights the commercial value of T-cell redirecting bispecific antibody immunotherautics in terms of drug prices, sales, company acquisition prices, economic terms of partnering deals, and private or public financing rounds.

About La Merie

La Merie Publishing is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com and www.PipelineReview.com, the Biologics News Center and Online Store of La Merie Publishing.

SOURCE: La Merie Publishing

Page 1 of 3

La Merie Publishing 
· Badstrasse 11 · 97990 Weikersheim · Germany · T +49-711-1289 0987 ·
 F +49-3212-1267 572 · publishing@lamerie.com